A universal vaccine to protect against all types of influenza A and B
Universal Influenza A/B Vaccine
This study is working on a new flu vaccine that could protect against different types of the virus by using a special method to deliver the vaccine directly to your skin, and it's currently being tested in animals before it can be tried in people.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orlance, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10846562 on NIH RePORTER |
What this research studies
This research focuses on developing a universal influenza vaccine that targets conserved antigens of influenza viruses to generate strong immune responses. The approach involves using DNA vaccination delivered through an innovative Gene Gun device, which enhances the immune response by effectively targeting skin cells and antigen-presenting cells. The project aims to create a comprehensive vaccine that provides protection against both influenza A and B types, with initial testing conducted in animal models before advancing to human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for influenza, such as the elderly, young children, and those with compromised immune systems.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated with existing influenza vaccines may not receive significant benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that provides broad protection against all strains of influenza A and B, potentially reducing the incidence of flu-related illnesses.
How similar studies have performed: Other research has shown promise in developing universal influenza vaccines, but this specific approach using DNA vaccination and the Gene Gun device is relatively novel.
Where this research is happening
Seattle, United States
- Orlance, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Bagley, Kenneth C — Orlance, INC.
- Study coordinator: Bagley, Kenneth C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.